Juan Carlos Montero

List of Publications by Year in Descending Order

54 papers	2,067 citations	26 h-index	45 g-index
55 ext. papers	2,288 ext. citations	6 avg, IF	4.4 L-index

#	Paper	IF	Citations
54	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 106	12.8	0
53	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. *Biomedicine and Pharmacotherapy*, **2021**, 144, 112330	7.5	0
52	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 106	12.8	4
51	PDCD4 limits prooncogenic neuregulin-ErbB signaling. *Cellular and Molecular Life Sciences*, **2021**, 78, 1799-1815	10.3	2
50	Altered proTGF/cleaved TGF ratios offer new therapeutic strategies in renal carcinoma. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 256	12.8	0
49	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 5096-5108	12.9	2
48	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 3117-3127	5.6	6
47	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. *Cancer Letters*, **2020**, 491, 50-59	9.9	5
46	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 383	12.8	32
45	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. *Breast Cancer Research and Treatment*, **2019**, 174, 693-701	4.4	18
44	The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. *Molecular Oncology*, **2018**, 12, 1061-1076	7.9	4
43	Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. *Molecular Oncology*, **2017**, 11, 1788-1805	7.9	5
42	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 2552-2562	6.1	32
41	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. *Oncotarget*, **2017**, 8, 29679-29698	3.3	8
40	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. *Oncotarget*, **2017**, 8, 19478-19490	3.3	22
39	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. *Molecular Cancer Therapeutics*, **2016**, 15, 1823-33	6.1	20
38	Multisite phosphorylation of P-Rex1 by protein kinase C. *Oncotarget*, **2016**, 7, 77937-77949	3.3	6

37	Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies. *Oncotarget*, **2016**, 7, 45042-45051	3.3	14
36	Targeting the EGF/HER Ligand-Receptor System in Cancer. *Current Pharmaceutical Design*, **2016**, 22, 5887-5898	3.3	35
35	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. *Oncotarget*, **2015**, 6, 27923-37	3.3	19
34	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. *Oncotarget*, **2015**, 6, 30057-71	3.3	13
33	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. *Oncotarget*, **2015**, 6, 31272-83	3.3	6
32	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. *Oncotarget*, **2015**, 6, 32856-67	3.3	15
31	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. *BMC Cancer*, **2014**, 14, 302	4.8	37
30	AchillesTheel of triple negative cancer. *Oncoscience*, **2014**, 1, 763-4	0.8	2
29	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. *Cellular Signalling*, **2013**, 25, 2281-9	4.9	14
28	Molecular pathways: P-Rex in cancer. *Clinical Cancer Research*, **2013**, 19, 4564-9	12.9	20
27	Lapachone analogs with enhanced antiproliferative activity. *European Journal of Medicinal Chemistry*, **2012**, 53, 264-74	6.8	29
26	Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. *Molecular Cancer Therapeutics*, **2012**, 11, 1342-52	6.1	38
25	Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. *Clinical Cancer Research*, **2011**, 17, 5546-52	12.9	204
24	Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains. *Journal of Biological Chemistry*, **2011**, 286, 24350-63	5.4	3
23	Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. *Journal of the National Cancer Institute*, **2010**, 102, 1432-46	9.7	39
22	Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 3835-9	8.3	17
21	Enhancement of antiproliferative activity by molecular simplification of catalpol. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2515-23	3.4	16
20	Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. *PLoS ONE*, **2009**, 4, e5565	3.7	76

19	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. *Blood*, **2009**, 113, 3781-91	2.2	66
18	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. *British Journal of Haematology*, **2008**, 141, 470-82	4.5	33
17	Neuregulins and cancer. *Clinical Cancer Research*, **2008**, 14, 3237-41	12.9	81
16	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. *Haematologica*, **2008**, 93, 57-66	6.6	50
15	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. *Cancer Research*, **2008**, 68, 5216-25	10.1	79
14	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. *Haematologica*, **2008**, 93, 851-9	6.6	26
13	Erk5 is activated and acts as a survival factor in mitosis. *Cellular Signalling*, **2007**, 19, 1964-72	4.9	26
12	Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 2656-63	2.2	51
11	The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. *Molecular Biology of the Cell*, **2007**, 18, 380-93	3.5	22
10	Multifunctional role of Erk5 in multiple myeloma. *Blood*, **2005**, 105, 4492-9	2.2	70
9	N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. *Biochemical Journal*, **2005**, 389, 161-72	3.8	17
8	Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. *Cancer Research*, **2005**, 65, 6801-10	10.1	59
7	Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. *Molecular and Cellular Biology*, **2002**, 22, 270-85	4.8	144
6	Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. *Molecular Biology of the Cell*, **2002**, 13, 2031-44	3.5	251
5	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. *Biochemical Journal*, **2002**, 363, 211-21	3.8	37
4	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. *Biochemical Journal*, **2002**, 363, 211-221	3.8	47
3	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. *Biochemical Journal*, **2000**, 346, 359-367	3.8	57
2	Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. *Molecular and Cellular Neurosciences*, **2000**, 16, 631-48	4.8	147

1	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. *European Journal of Neuroscience*, **1999**, 11, 1421-30	3.5	41